World Pharmaceuticals Market Brief

World Pharmaceuticals Market Brief

The global outlook series on Pharmaceuticals provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report provides a bird’s eye view of the pharmaceutical industry, and highlights global trends impacting the marketplace, such as, patent expiry of blockbuster global drugs, rising demand for old age related medications and cardiovascular drugs, and the rise of biogenerics, among others. A briefly summarized outlook presents unequivocal views on the industry’s future. Punctuated with 18 statistically rich tables, the global market discussion offers special preludes to major market segments, such as, Prescription Drugs, Blockbuster Drugs, Anti-Depressants, COPD, Cholesterol Drugs, CNS Drugs, Cardiovascular Drugs, Cancer Drugs, Attention Deficit Hyperactive Disorder, Artherosclerosis, Asthma, Anti-Infective Prescription Agents, Receptor Blockers, Psychotic Disorders, Osteoporosis, Multiple Sclerosis, Irritable Bowel Syndrome, Insomnia, Immunosupression Hypertension, Epilepsy, Rhinitis, Urinary Disorders, HIV/AIDS, and Diabetes among others. Also included is a recapitulation of recent mergers, acquisitions, and other noteworthy strategic corporate developments. Annotated with quantitative analysis and research findings, the discussion on the US market contains 46 market data tables designed to give the reader a macro level understanding of the market. Other regional markets covered include Canada, Japan, Western Europe, Switzerland, UK, China, India, Korea, Malaysia, and Brazil. The purpose of the abstracted regional market discussion is to provide the reader an introduction to these markets. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 3,083 companies worldwide.

PHARMACEUTICALS GOS-041
A GLOBAL OUTLOOK, SEPTEMBER 2008


CONTENTS


1. Overview 1
Table 1: Global Pharmaceutical Market (2006): Sales in US$
Billion by Region - US, Europe, Japan, Asia-Pacific, Latin
America, Middle East/Africa and Canada 1
US Leads the Pharmaceuticals Sector 1
Global Trends in Pharmaceutical Industry 1
Aging World Population Drives Up Demand for Pharmaceuticals 1
Market Booming for Old Age Related Medications 2
BRIC Countries to Drive Up the Pharmaceuticals Sector 2
China and India Emerge as Major Contract Manufacturing Hubs 2
Rising Consumer Health Consciousness Drives Up the OTC Drugs
Sector 2
Market Growing for OTC Scar Management Solutions 3
Market Growing for Artificial Tears 3
Faster Drug Approval Process, the Need of the Hour 3
Cardiovascular Drugs Still Rules the Roost 3
Global Analgesics Market to Soar 3
Market Growing for Antidepressants 4
New R&D Initiatives To Spark Up Growth 4
Acquisitions and Mergers Propels the Pharmaceuticals Sector 5
Generics Expand Share 5
Table 2: Increasing Share of Generics in the Global
Pharmaceutical Market: 1995-2006 (In %) 6

Table 3: Global Generic Drugs Market by Geographic Region:
Annual Sales Estimates in US$ Million for 2003 through 2008
for USA, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World 6

Table 4: Global Generic Drugs Market (2005 & 2006):
Percentage Breakdown of Value Sales by Therapeutic Category
- Cardiovascular, Anti-Infective, Analgesic, Central Nervous
System (CNS), Gastrointestinal, Cancer, Respiratory &
Anti-Allergic, and Others 7
Global Patent Expiries of Select Major Drugs: 2007-2012 7
Major Generic Drugs 8
Table 5: Leading Generic Drugs Worldwide by Retail Sales
(2005): Hydrocodone/APAP, Gabapentin, Amoxicillin/pot.
clav., Paroxetine, Oxycodone, Lisinopril, Metformin,
Omeprazole, Fentanyl transdermal, Amoxicillin, Fluoxetine,
Oxycodone w/ APAP, Albuterol aerosol, Lovastatin,
Levothyroxine, Lorazepam, Atenolol, Alprazolam, Cephalexin,
and Warfarin 8

Table 6: Leading Generic Drugs Worldwide by Total Units
Dispensed (2005): Annual Estimates in Millions for
Hydrocodone/APAP, Amoxicillin, Peg 3350/electrolyte,
Metformin, Alprazolam, Lisinopril, Atenolol,
Hydrochlorothiazide, Furosemide Oral, Chlorhexidine
Gluconate, Gabapentin, Ibuprofen, Levothyroxine,
Metoprololtartrate, Albuterol nebulizer solution,
Propoxyphene-N/APAP, Potassium chloride, Cephalexin,
Amoxicillin/pot. Clav., and Tramadol 9
Leading Generic Drug Companies 10
Table 7: Leading Companies in the Global Generic Drugs
Market (2005): Percentage Breakdown by Value Sales for
Sandoz, Teva Pharmaceutical Industries, Merck Generics,
Actavis, Ratiopharm, Mylan Laboratories, IVAX, Barr
Pharmaceuticals, Ranbaxy Laboratories, and Others 10

Table 8: Leading Companies in the Global Generics
Pharmaceutical Market by Number of Prescriptions Dispensed
(2005): Annual Estimates in Millions for Teva/Ivax, Mylan,
Sandoz, Watson, Mallinckrodt, Alpharma, Qualitest, Par,
Barr, Laboratories, and URL/Mutual 10
Generic Competition Provides the Necessary Momentum 11
Authorized Generics - A Major Concern for Generic Makers 11
Regulatory Reform Drive the European Market 11
New Areas of Expertise 11
Biogeneric Revolution 11
Bio-generics to Exhibit Slow Start 11
Biogeneric Market Trends Worldwide: 2005-2010 12
Select Global Biotech Drugs Off-Patent: 2001-2006 12
Potentially Key Competitors in the Biogenerics Space: 2005-2010 12
Product Lifecycle Management - The Deciding Factor 13
Table 9: TOP 10 Pharmaceutical Products Worldwide in 2004 13
Packaging Trends 14
Blister Packaging to Record High Growth 14
Table 10: Global Pharmaceutical Packaging Demand by Country:
Percentage Market Share for 2005, 2008, and 2010 for
Europe, North America, Latin America, and Others 14
Outlook 15
Pharmacogenomics to Substitute Pharma’s Business Model 15
Biopharmaceuticals - The Next Generation 15
Table 11: Global Demand for Biopharmaceuticals: Annual
Market Estimates for 2004 through 2010 in Millions of Liters 16
Nano-Enabled Drug Discovery Geared to Lead 16
Proteomics - The Current Spotlight 16
Neurodegeneration Treatments Identified in Research 17
Table 12: Leading Companies in the Global Pharmaceutical
Market by Healthcare Research and Development (R&D) Spending
(2005): Annual Estimates in US$ Million for Pfizer Inc.,
Johnson & Johnson, GlaxoSmithKline Plc, Sanofi-Aventis
Group, Novartis, Roche, Merck & Co., AstraZeneca Plc, Eli
Lilly and Co., Wyeth, Bristol-Myers Squibb Co., Amgen Inc.,
Schering-Plough Corp., Abbott Laboratories, Boehringer
Ingelheim GmbH, Takeda Pharmaceutical Co., Daiichi Sankyo
Co., Genentech Inc., Schering AG, and Astellas Pharma Inc. 17

2. Major Class of Drugs 18
Antidepressants 18
Antiepileptics 18
Antipsychotics 18
Antirheumatic Non-steroidals 18
Antulcerants 18
Calcium Antagonists 18
Erythropoietins 18
Oral Antibiotics 18
Lipid Regulators 18
Antiarthritics 18
Antihistamines 18
Antihyperlipidemics 18
Oral Antidiabetics 18

3. Geographical Landscape 19
Table 13: Global Pharmaceutical Market by Region/Country
(2005): Annual Sales in US$ Billion for United States, Europe,
Japan, Asia-Pacific, Latin America, Middle East/Africa, and
Canada 19

Table 14: Global Pharmaceutical Market by Region/Country
(2005): Percentage Breakdown of Value Sales for United States,
Europe, Japan, Asia Pacific, Latin America, Middle
East/Africa, and Canada 19
Leading Global Pharmaceutical Players 19
Table 15: Leading Global Pharmaceutical Companies by Revenue
(2006): Annual Estimates in US$ Billion for Pfizer,
GlaxoSmithKline, Novartis, Sanofi-Aventis, Johnson & Johnson,
AstraZeneca, Merck, Roche, Abbott, and Amgen 20

Table 16: Leading Global Pharmaceutical Companies by Net
Income (2005): Annual Estimates in US$ Million for Johnson &
Johnson, GlaxoSmithKline Plc, Procter & Gamble Co., Pfizer
Inc., Novartis, Roche, AstraZeneca Plc., Merck & Co., Amgen
Inc., Wyeth, Abbott Laboratories, Bristol-Myers Squibb Co.,
Sanofi-Aventis Group, Takeda Pharmaceutical Co., and Bayer 20

Table 17: Leading Global Pharmaceutical Companies by Market
Capitalization (2006): Annual Estimates in US$ Million for
Pfizer Inc., Procter & Gamble Co., Johnson & Johnson,
GlaxoSmithKline Plc., Novartis, Sanofi-Aventis Group,
AstraZeneca Plc, Merck & Co., Genentech Inc., Amgen Inc.,
Abbott Laboratories, Wyeth, Eli Lilly and Co., Bristol-Myers
Squibb Co., and Bayer 21

Table 18: Leading Global Pharmaceutical Companies by
Shareholders' Equity (2005): Annual Estimates in US$ Million
for Pfizer Inc., Procter & Gamble Co., Sanofi- Aventis Group,
Johnson & Johnson, Roche, Novartis, Amgen Inc., Takeda
Pharmaceutical Co, Merck & Co., Abbott Laboratories, Bayer,
AstraZeneca Plc., GlaxoSmithKline Plc., Wyeth, and
Bristol-Myers Squibb Co. 21

Table 19: Leading Global Pharmaceutical Companies by
Aggregate Assets (2005): Annual Estimates in US$ Million for
Procter & Gamble Co., Pfizer Inc., Sanofi-Aventis Group,
Johnson & Johnson, Novartis, Roche, GlaxoSmithKline Plc.,
Bayer, Merck & Co., Wyeth, Amgen Inc., Abbott Laboratories,
Bristol-Myers Squibb Co., Takeda Pharmaceutical Co., and
AstraZeneca Plc 22

Table 20: Leading Global Pharmaceutical Companies by Number
of US-dispensed Prescriptions (2005): Annual Estimates in
Millions for Pfizer, Novartis, Teva, Mylan Laboratories,
Watson, GlaxoSmithKline, Merck & Company, Ivax Corporation,
AstraZeneca, Mallinckrodt, Johnson & Johnson, Sanofi-Aventis,
Barr Laboratories, Abbott Laboratories, and Alpharma USPD 22

Table 21: Leading Global Pharmaceutical Companies by
Direct-to-consumer Advertisement Spending (2005): Annual
Estimates in US$’000 for GlaxoSmithKline, Pfizer,
AstraZeneca, Sanofi-Aventis, Merck & Co., Johnson & Johnson,
Novartis, Sepracor, Merck/Schering-Plough Pharmaceuticals,
Amgen, Schering-Plough, Allergan, Lilly Icos, Abbott
Laboratories, Wyeth, Eli Lilly, Roche, Procter & Gamble, Tap
Pharmaceutical Products, and Astellas Pharma 23

4. Mergers and Acquisitions 24

5. Strategic Corporate Developments 76

6. Product Launches 105

7. Review of Select Segments 109
Prescription Drugs 109
Market Overview 109
Table 22: Global Leading Prescription Drug Brand Sales by
Category: Annual Market Estimates for 2003 through 2008 in
Billions of US$ for Cardiovascular, Hypertension Drugs,
Anti-Infective, Psychotherapeutic Agents, Gastrointestinal
Therapies, Respiratory Products, and Cholesterol
Reduction. 109

Table 23: Global Leading Prescription Drugs Sales by
Therapeutic Category (Blood Modifiers): Annual Market
Estimation for 2003 through 2008 in Millions of US$ for
Anemia, Deep Vein Thrombosis, Hemophilia, Occlusive Arterial
Disease, Pulmonary Embolism, Leukopenia, Iron Intoxication,
White Blood Cell Enhancement and Peripheral Disease. 110
Blockbuster Drugs 110
Market Overview 110
Table 24: Global Drugs Gaining Blockbuster Status by Sales:
Annual Market Estimates for 2003 through 2008 in Billions of
US$ for Advair/Seretide, Nexium, Plavix, Singulair,
Mabthera/Rituxan, Lovenox/ Clexane, Ambien/Stilnox,
Wellbutrin, and Others 111

Table 25: Global Top-Selling Drugs Value Sales: Annual
Market Estimates for 2003 through 2008 in Billions of US$
for Chiral, Racemic, and Achiral Drugs 112
Antidepressants 112
Market Overview 112
Leading Antidepressants Worldwide and Year of Patent Expiry 112
Chronic Obstructive Pulmonary Disease 113
Market Overview 113
Table 26: Global Chronic Obstructive Pulmonary Disease Drug
Sales by Leading Category: Annual Market Estimates for 2003
through 2008 in Millions of US$ for Beta2-agonists,
Anticholinergics, Corticosteroids, Methyl Xanthines and
Leukotinene Antagonists 113
Cholesterol Drugs 113
Market Overview 113
Leading Cholesterol Drugs Worldwide and Year of Patent Expiry 114
CNS Drugs 114
Market Overview 114
Table 27: Global Leading Central Nervous System Prescription
Drugs Sales by Symptoms: Annual Market Estimates for 2003
through 2008 in Millions of US$ for Depression, Psychotic
disorders, Epilepsy, Migraine, Insomnia, Anesthesia,
Anxiety, Alzheimer disease, Attention deficit hyperactivity
disorder, and Dystonia 114
Cardiovascular Drugs 115
Market Overview 115
Leading Cardiovascular Prescription Drugs 115
Cancer Drugs 115
Market Overview 115
Attention Deficit Hyperactive Disorder 115
Market Overview 115
Artherosclerosis 115
Market Overview 115
Asthma 115
Market Overview 115
Leading Brands 116
Asthma Drug Sales by Respiratory Category 116
Table 28: Global Asthma Drug Value Sales by Respiratory
Category: Annual Market Estimates for 2003 through 2008 in
Millions of US$ for Inhaled Corticosteroids, Short Acting
Beta Agonists, Long Acting Beta Agonists, Combinations,
Anti-Leukotrienes and Other Asthma Therapeutics 116
Antinfective Prescription Agents 116
Market Overview 116
Table 29: Global Leading AntInfective Prescription Agents
Sales for Various Symptoms: Annual Market Estimates for 2003
through 2008 in Millions of US$ for Bacterial Infections,
Viral Infections and Fungal Infections 117
Receptor Blockers 117
Market Overview 117
Table 30: Receptor Blockers Value Sales in the Global
Market: Annual Market Estimates for 2003 through 2008 in
Billions of US$ 117
Psychotic Disorders 118
Market Overview 118
Worldwide Leading Prescription Drugs for Psychotic Disorders
and Year of Patent Expiry 118
Osteoporosis 118
Market Overview 118
Multiple Sclerosis 118
Market Overview 118
Table 31: Global Sales of Leading Prescription Drugs for
Multiple Sclerosis in Millions of US$:) 2005 119

Table 32: Global Leading Prescription Drug Sales for
Multiple Sclerosis: Annual Market Estimates for 2003 through
2008 in Millions of US$ 119
Irritable Bowel Syndrome 119
Market Overview 119
Table 33: Global Leading Drug Value Sales by Category for
Treating Irritable Bowel Syndrome: Annual Market Estimates
for 2003 through 2008 in Millions of US$ for Laxatives,
Antidiarrheals, and Antidepressants 120

Table 34: Global Leading Drug Value Sales by Category for
Treating Irritable Bowel Syndrome: Percentage Market Share
for 2004 and 2008 for Laxatives, Antidiarrheals, and
Antideoressants 120
Insomnia 121
Market Overview 121
Immunosuppression 121
Market Overview 121
Table 35: Global Leading Prescription Drugs for
Immunosuppression by Sales: Annual Market Estimates for 2003
through 2005 in Millions of US$ for Neoral/ Sandimmun,
Cellcept, Prograf and Medrol 121
Hypertension 121
Market Overview 121
Table 36: Global Value Sales of Leading Prescription Drugs
for Hypertension: 2004 and 2005 in Millions of US$ for
Norvasc (Pfizer), Diovan/Co-Diovan (Novartis), Cozaar and
Hyzaar (Merck & Co.), Prinivil and Prinzide (Merck & Co.),
Lotensin/Cibacen and Lotrel (Novartis), Toprol-XL/Seloken
(AstraZeneca), Tritace/Delix, Blopress (Takeda Chemical
Industries), Zestril (AstraZeneca), Vasotec and Vaseretic
(Merck & Co.), and Accupril and Accuretic (Pfizer) 122
Epilepsy 122
Market Overview 122
Leading Prescription Drugs for Epilepsy and Year of Patent
Expiry 123
Rhinitis 123
Market Overview 123
Urinary Disorders 123
Market Overview 123
Table 37: Global Leading Prescription Drugs Sales for
Urinary Disorders by Symptoms: Annual Market Estimates for
2003 through 2008 in Millions of US$ for Benign Prostatic
Hypertrophy and Overactive Bladder 123
HIV/AIDS 124
Market Overview 124
FDA Sanctions Fast Track Status to First-in-Class HIV Drug 124
Diabetes 124
Table 38: Global Sales of Medications for Diabetes by
Segment: Percentage Market Share for 2005, 2008, and 2010 for
Oral Ant Diabetic Drugs, and Insulin Products 124

Table 39: Global Sales of Medications for Diabetes by
Segment: Annual Market Estimates for 2004 through 2010 in
Billions of US$ for Oral Anti Diabetic Drugs, and Insulin
Products 124

8. United States 125
Table 40: US Drug Market (2006): Chain Drug Stores Sales in
US$ Billion by Product Category-Total Prescription
(Prescription drugs--brand, Prescription drugs--brand,
specialty, Prescription drugs--generic), Nonprescription
drugs, Health and personal care, General merchandise, DME and
HHC and Other 125

Table 41: US Pharmaceutical Market (2006): Percentage
Breakdown of Value Sales by Therapic Category- Lipid
Lowerers--Statins+ZET, Proton Pump Inhibitors,
Anti-Depressants, Antipsychotics, 0TH, Erythropoietins,
Seizure Disorders, Antineo Monoclonal Antib, Angiotensin II
Antag, Insulin Sensitizer, Calcium Blockers, Antiarth, BIOL
RESPMOD, Bisphosphonates, Anti-Platelets, Oral, Immune System
Adjuncts, Steroid, Inhaled BronchC, ACE Inhibitors, Non-Barb,
0TH, GI Anti- Inflammatory, Aanaleptics, Immunologic
Interferons and Others 126
Lower Margins in the US leads to Consolidation and
Diversification in the Global Market 126
Beset with Setbacks 126
Regulations Shaping the US Pharmaceutical Industry 127
Medicare Drug Improvement and Modernization Act (MMA) 127
The American Jobs Creation Act of 2004 127
Autonomous Panel for Screening Drug Safety 127
GPhA Drives FDA to Back Generic Drugs 127
Rapid Surge in ANDAs 127
Competitive Scenario 127
Table 42: US Pharmaceutical Market (2006): Sales In US$
Million for Major Distributors- McKesson Pharmaceutical
Solutions, Cardinal Health, AmerisourceBergenDrug, Kinray and
HD Smith Wholesale Drug 128

Table 43: Leading Pharmaceutical Companies in the US by
Branded Drug Sales (2006): Annual Estimates in US$ Million
for GlaxoSmithKline, Abbott, Forest, Monarch, Dey
Laboratories, Bausch & Lomb, Ivax Laboratories, Roxane, Taro
USA, Par, Mylan, Repacker, Bertek, Alpharma US, Mallinkrodt,
Xanodyne, Pharmaderm, Morton Grove, Dava, and Lupin 129

Table 44: Leading Pharmaceutical Companies in the US by Total
Drug Sales (2006): Annual Estimates in US$ Million for
GlaxoSmithKline, Teva USA, Abbott, Mylan, Sandoz, Watson
Laboratories, Forest, Par, Barr, Ivax, Greenstone, Monarch,
Mallinkrodt, Ranbaxy, Apotex, Eon Laboratories, Qualitest,
Endo Generic, Pliva, and Danbury 130

Table 45: Leading Vendors in the US Athlete's Foot/foot Care
Medication Market (2006): Sales through Drugstores in US$'
000 for Schering-Plough, Novartis Consumer Health, NDC
Laboratories, Combe, Miracle of Aloe, Taro Pharmaceuticals,
Chattem, Del Laboratories, Eulactol USA, and Alva/Amco 130

Table 46: Leading Vendors in the US Athlete's Foot/foot Care
Medication Market (2006): Sales through Drugstores in ‘000
Units for Schering-Plough, Novartis Consumer Health, Combe,
Chattem, Del Laboratories, Taro Pharmaceuticals, Miracle of
Aloe, Eulactoi USA, Pfizer, and NDC Laboratories 131
Pharmaceuticals Market by Therapeutic Category 131
Table 47: United States Pharmaceuticals Market by Leading
Therapeutic Category (2005): Annual Sales in US$ Billion for
Statins, Proton Pump Inhibitors, Antipsychotics,
Antidepressants, Erythropoietins (cancer), Seizure
Disorders, Angiotensin II Antagonists (anti-hypertensives),
Calcium blockers, Insulin Sensitizers, and Monoclonal
antibodies (cancer) 131

Table 48: United States Pharmaceuticals Market (2005):
Percentage Breakdown of Drug Spending by Therapeutic Category
- Cardiovascular, CNS: Neurology, Mental Health & Pain,
Gastro-enterology, Respiratory & Allergy, Endocrine &
Diabetes, Anti-infectives, Rheumatology & Musculoskeletal,
and Others 132
Leading Drugs 132
Table 49: Leading Branded Drugs in the US Pharmaceuticals
Market (2005): US Sales in US$ Billion for Lipitor, Zocor,
Nexium, Prevacid, Advair, Plavix, Zoloft, Epogen, Procrit,
and Aranesp 132

Table 50: Leading Drug Classes by Prescriptions Volume in the
US: Annual Market Estimates for 2003 through 2008 in Millions
of Numbers for Codeine & Comb Non-Inj, Ssris / Snris, Cholest
Rdcr Statins, Ace Inhib W / O Diuret, Beta-Blockers, O /C
Estr / Progest, Calcium Blockers, Thyroid. Synthetic,
Antihistamine Cap-Tab, and Proton Pump Inhibitors 133

Table 51: Leading Brands in the US First Aid
Ointments/antiseptics Market (2006): Sales through Drugstores
in US$'000 for Neosporin Plus, Neosporin, Mederma, Aquaphor,
Polysporin, Solarcaine, Hibiclens, Betadine, BD, and Bactine 133

Table 52: Leading Brands in the US First Aid
Ointments/antiseptics Market (2006): Sales through Drugstores
in ‘000 Units for Neosporin Plus, Neosporin, BD, Aquaphor,
Polysporin, Solarcaine, Mederma, Bactine, Hibiclens, and
Bladex 134

Table 53: United States’ Leading Cough Syrup Brands (2005):
Sales through Drugstores in US$ Million for Robitussin OM,
Delsym, Robitussin, Vicks NyQuil Cough, Diabetic Tussin,
Zicam, Cough Mist, Vicks Formula 44, Vicks Formula 44e,
Robitussin Pediatric, and Robitussin Honey Cough 134

Table 54: United States’ Leading Cough Syrup Brands (2005):
Sales through Drugstores in Units for Robitussin OM,
Robitussin, Delsym, Vicks NyQuil Cough, Vicks Formula 44,
Vicks Formula 44e, Diabetic Tussin, Robitussin Pediatric,
Robitussin Honey Cough, Zicam Cough Mist 135

Table 55: Leading Brands in the US Ear Drops/treatments
Market (2006): Sales through Drugstores in US$ for Similasan,
Debrox, Murine, Hyland, Swim Ear, Physicians Choice, Auro
Dri, Otix, Auro, and Clear Tinnitus 135

Table 56: Leading Brands in the US Ear Drops/treatments
Market (2006): Sales through Drugstores in Units for
Similasan, Debrox, Swim Ear, Murine, Auro Dri, Hyland,
Physicians Choice, Otix, Auro, and Clear Tinnitus 135

Table 57: United States’ Leading Oral Pain Relief Brands
(2005): Sales through Drugstores in US$'000 for Orajel,
Anbesol, Baby Oraj, Peroxyi, Zilactin, Temparin, Glyoxide,
Dentemp, Kank-A, and Hyland's 136

Table 58: United States’ Leading Oral Pain Relief Brands
(2005): Sales through Drugstores in ‘000 Units for Orajel,
Anbesol, Baby Orajel, Peroxyl, Temparin, Dentemp, Hyland's,
Zilactin, Kank-A, and Glyoxide 136

Table 59: Leading Brands in the US Weight Control
Candy/Tablet Market (2005): Sales through Drug Stores in US$
Million for Relacore, Cortislim, Zantrex 3, Trim Spa X32,
Hydroxycut, Trim Spa, Xenadrine EFX, Metabolife Ultra, Estrin
D, and Stacker 2 137

Table 60: Leading Brands in the US Weight Control
Candy/Tablet Market (2005): Sales through Drug Stores in
Units for Relacore, Trim Spa X32, Cortislim, Zantrex 3,
Metabolife Ultra, Hydroxycut, Xenadrine EFX, Stacker 2,
Trim Spa, and Estrin D 137

Table 61: United States’ Leading Nasal Aspirator Brands
(2005): Sales through Drug Stores in US$ for Luv N Care,
First Years, Safety 1st, Little Noses, Ross, Gerber,
Sunmark, Cara, and Acu Life 138

Table 62: United States’ Leading Nasal Aspirator Brands
(2005): Sales through Drug Stores in Units for Luv N Care,
First Years, Safety 1st, Little Noses, Gerber, Ross, Sunmark,
Cara, and Acu Life 138

Table 63: Leading Brands in the US Eye/Lens Care Solutions
Market (2006): Sales through Drug Stores, Supermarkets, and
Discount Stores (excluding Wal-Mart) in US$ Million for Alcon
Opti-Free Express, Bausch & Lomb Renu Multiplus, Amo Complete
Moisture Plus, Alcon Systane, Allergan Refresh Tears, Clear
Eyes, Alcon Opti-Free Replenish, Ciba Vision Clear Care,
Visine Advanced Relief, and Visine 139

Table 64: Leading Brands in the US Eye/Lens Care Solutions
Market (2006): Sales through Drug Stores, Supermarkets, and
Discount Stores (excluding Wal-Mart) in Million Units for
Alcon Opti-Free Express, Bausch & Lomb Renu Multiplus, Clear
Eyes, Visine Advanced Relief, Visine, Amo Complete Moisture
Plus, Alcon Opti-Free Replenish, Alcon Systane, Ciba Vision
Clear Care, and Allergan Refresh Tears 139
Consumer Healthcare 140
Table 65: Pharmaceutical Product Sales by Category through
Food, Drug and Mass Merchandise Stores in the US: Annual
Market Estimates for 2003 through 2008 in Millions of US$ for
Vitamins, Cold/Allergy/Sinus Tablets, Skin Care,
Gastrointestinal - Tablets, Weight Control/ Nutrition Liquid/
Powder, First Aid Accessories, Miscellaneous Health Remedies,
First Aid Treatment, Cold/Allergy/Sinus Liquids,
Gastrointestinal - Liquid and Cough Drops 140
Packaging 140
Table 66: Pharmaceutical Industry’s Packaging Demand by Type
in the US: Annual Market Estimates for 2003 through 2008 in
Millions of US$ for Blister Packaging, Plastic Bottles,
Secondary Containers and Other Primary Containers 140
Leading Distribution Channels 141
Table 67: United States’ Pharmaceuticals Market by Retail
Outlet (2005): Percentage Breakdown of Value Sales for
Traditional Drug Chains, Mail Order/Internet, Independent
Drug Stores, Supermarkets, and Mass Merchants 141

Table 68: Prescription Pharmaceutical Sales through
Retail/Distribution Channel in the US: Percentage Market
Share for 2004 and 2005 for Chains, Indep., Non-Fed Hosp.,
Mail Order, Food Stores, Clinics, LTC, HMO, Fed. Facilities,
and Others 141

Table 69: Leading Pharmacy Chains in the United States
(2005): Retail Rx Sales in US$ Million for CVS Corp.,
Walgreens, Wal-Mart, Rite Aid, Brooks-Eckerd, Kroger,
Supervalu, Safeway, Medicine Shoppe, and Sears Holdings 142
Promotional Expenditure 142
Table 70: United States’ Pharmaceutical Advertising
Expenditure through Medical Journals for 2003 through 2005
(In US$ ‘000) 142
External Analgesics 143
Table 71: External Analgesics Sales through Distribution
Channel in the US: Percentage Market Share for 2004 and 2005
for Mass Merchandise, Food and Drug Stores 143

Table 72: Leading External Analgesics Drug Brand Volume Sales
in the US: Percentage Market Share for 2004 and 2005 for
Bengay, Joint-Ritis, Icy Hot, Aspercreme, Flex All 454,
Mineral Ice, Salonpas, Absorbine Jr., Sportscreme, and Others 143
Internal Analgesics 144
Table 73: United States’ Leading Internal Analgesic Liquid
Brands (2005): Sales through Drugstores in US$ Million for
Children's Motrin, Tylenol, Children's Tylenol, Infant's
Motrin, Children's Advil, Advil, Gel Stat, Tylenol PM,
Elixsure, and Motrin 144

Table 74: United States’ Leading Internal Analgesic Liquid
Brands (2005): Percentage Breakdown of Volume Sales through
Drugstores for Children's Motrin, Tylenol, Children's
Tylenol, Infant's Motrin, Children's Advil, Advil, Gel Stat,
Tylenol PM, Elixsure, and Others 144
Cancer Therapeutics 145
Table 75: Number of New Cases of Cancer Reported in the US:
2005 in Thousands for Non-melanoma Skin Cancer, Recurrent
Colon Polyps, Prostate Cancer, Superficial Bladder Cancer,
Barrett's Esophagus Cancer, and Others 145

Table 76: Top Cancer Incidence Types in the US: 2005 per
100,000 People for Prostate, Breast, Lung, Colon & rectum,
and Testis 145
Generic Drugs 146
Market Highlights 146
Table 77: United States Market for Generic Drugs by
Therapeutic Category: Annual Sales Estimates in US$ Million
for 2003 through 2008 for Cardiovascular, Analgesic,
Anti-Infective, Central Nervous System (CNS),
Gastrointestinal, Respiratory & Anti- Allergic, Cancer and
Others 146

Table 78: United States Generic Cardiovascular Drugs Market
(2005): Percentage Share Breakdown by Segment - Beta
Blockers and ACE Inhibitors; Calcium Channel Blockers;
Angina and Arrhythmia Drugs; Diuretics; Vasodilators,
Vasopressors, and Anticoagulants 147

Table 79: United States Generic Central Nervous System (CNS)
Drugs (2005): Percentage Breakdown by Segment -
Sedatives/Hypnotics, Tranquilizers and Antianxiety Agents,
Antidepressants, Stimulants, and Antipsychotics, and
Anticonvulsants, Antispasmodics and Muscle Relaxants 147

Table 80: United States Generic Gastrointestinal Drugs
(2005): Percentage Breakdown by Segment - Anti-Spasmodics
Drugs, Anti-Nauseants, Anti-Ulcer, Digestants, and
Anti-Diarrheals 148

Table 81: United States Market for Generic Ophthalmic Drugs
(2005): Percentage Breakdown by Segment - Glaucoma Drugs,
Anti-Infective, and Anti- Inflammatory Drugs and Mast Cell
Inhibitors 148
Leading Generic Manufacturers 148
Table 82: Leading Manufacturers in the US Generic Drugs
Market (2006): Percentage Breakdown by Prescriptions for
Teva, Mylan, Watson, Sandoz, Barr, Mallinckrodt, Actavis,
Qualitest, Par, Greenstone and Others 148

Table 83: Leading Players in the US Generic Drugs Market
(2005): Percentage Breakdown of Value Sales for Teva,
Novartis (Sandoz), Mylan, Watson, Ivax, Par, Pfizer
(Greenstone), Actavis, Boehringer Ingelheim, Baxter
Healthcare, and Others 149
Leading Drugs by Value Sales 149
Table 84: Leading Generic Drug in the US: 2005 Percentage
Market Share for Hydrocodone/ APAP, Ranitidine HCI,
Albuterol aerosol, Alprazelam, Lorazepam, Atenolol,
Propoxyphene- N/APAP, Tamoxifen, Cephalexin, & Others 149
Authorized Generics 150
Table 85: United States Generics Market (2003-2005): Growing
Share of Authorized Generics in the Total Market 150
Diabetes 150
Oral Diabetes Drugs 150
Key Players 150

9. Canada 151
Market Overview 151
Amendments to Canadian Drug Patent Laws 151
New Regulations Provide Accurate Timeline for Introduction
of Generics 151
Table 86: Canadian Market for Generic Drugs: Annual Sales
Estimates in US$ Million for Years 2003 through 2008 152

Table 87: Share of Generic and Branded Drugs in the
Canadian Prescription Drug Market: 2006 152

10. Japan 152
Market Overview 152
Table 88: Japanese Pharmaceuticals Market (2005): Percentage
Breakdown of Value Sales by Sector - Cardiovascular,
Alimentary/ metabolism, Central Nervous System, Respiratory,
and Others 153

Table 89: Japanese Pharmaceuticals Market: Percentage Share
of Bio-Pharmaceuticals in Total Drug Approvals for 2003,
2005, and 2008 153
Trends in Oncology Market 153
Table 90: Oncology Treatment in the Japan: Annual Market
Estimates for 2003 through 2008 in Billions of US$ 153

11. Europe 154
Market Overview 154
Table 91: European Pharmaceutical Market (2006): Sales in US$
Billion by Region- France, Germany, UK, Italy and Rest of
Europe 154

Table 92: Natural Ingredients Imports by Product Group in the
European Union: 2005 in Millions of Euros for Medicinal and
Aromatic Plants, and Others 154
Investments in R & D 154
Generic Drugs 155
Table 93: European Market for Generic Drugs by Therapeutic
Category: Annual Sales Estimates in US$ Million for 2003
through 2008 for Cardiovascular, Analgesic, Anti-Infective,
Central Nervous System (CNS), Gastrointestinal, Respiratory &
Anti-Allergic, Cancer and Others 155

11 a. Western Europe 155
Market Overview 155
Export Scenario 155
Research and Development Expenditure 156
Table 94: Pharmaceutical Research and Development Expenditure
by Country in Western Europe: Percentage Market Share for
2003, 2004 and 2005 for France, Germany, UK, Switzerland,
Belgium, and others 156
Generic Drugs 156
Table 95: Western European Market for Generic Drugs by
Country: Annual Sales Estimates in US$ Million for 2003
through 2008 for France, Germany, UK, Spain, and Italy 156

11b. Switzerland 157
Market Overview 157

11c. United Kingdom 157
Market Overview 157
Table 96: United Kingdom Pharmaceuticals Market (2003-2005):
Exports and Imports in £ Million 157
Over-The-Counter Medications 158
Table 97: Over-the Counter Volume Sales of Drugs by Category
in the UK: Annual Market Estimates for 2003 through 2008 in
Millions of Units for Gastro/ Intestinal, Cold/Cough, Eye
Care/Hayfever, Oral/ Topical Analgesics, FAD/Topical
Antiseptics and Other Defined Healthcare 158

Table 98: Over-the Counter Volume Sales of Drugs by Category
in the UK: Percentage Market Share for 2004 and 2008 (E) for
Gastro/ Intestinal, Cold/Cough, Eye Care/Hayfever,
Oral/Topical Analgesics, FAD/Topical Antiseptics and Other
Defined Healthcare 159

Table 99: Over-The-Counter Medication Value Sales in the UK:
Annual Market Estimates for 2003 through 2008 in Millions of
Pounds Sterling for Pain Relief, Skin Treatments,
Cough/Cold/Sore Throat, Gastro-Intestinal, Vitamins &
Minerals, Medicated Mouthwash/ Sprays, Hayfever Remedies, Eye
Care Treatment and Sleeping Aids 159

Table 100: Over-The-Counter Medication Value Sales in the UK:
Percentage Market Share for 2004 and 2008 for Pain Relief,
Skin Treatments, Cough/Cold/Sore Throat, Gastro-Intestinal,
Vitamins & Minerals, Medicated Mouthwash/Sprays, Hayfever
Remedies, Eye Care Treatment and Sleeping Aids 160
Analgesics 160
Table 101: Analgesics Value Sales through Drug Stores in the
UK: Annual Market Estimates for 2003 through 2008 in Millions
of Pounds Sterling for Adult Oral Analgesics, Pediatric
Analgesics, and Topical Analgesics 161
Oral Analgesics 161
Statin Drugs 161
Table 102: Leading Statin Drugs Average New Prescriptions in
the UK: 2004 2005 Percentage Market Share for Lipitor, Zocor,
Pravachol, Baycol, Lescol, and Mevacor 162

12. Asia/Asia-Pacific 162
Market Overview 162
Table 103: Asian Pharmaceuticals Market (2005): Percentage
Breakdown of Value Sales by Geographic Region/Country -
Japan, China, Australia, South Korea, and Rest of
Asia-Pacific 162
Generic Market - A Perspective 163

12a. China 163
Table 104: Chinese Pharmaceuticals Market: Annual Sales in US$
Billion for 2003 through 2005 164

Table 105: Chinese Market for Generic Drugs: Annual Sales
Estimates in US$ Million for Years 2003 through 2008 164

Table 106: Pharmaceuticals Industry Revenue by Province in
China: Percentage Market Share for 2005 for Guangdong
Province, Shanghai City, and Others 164
Trends 165
Demographics Encourage Growth 165
Table 107: Demographic Trends in China (2005-2010) 165
Stringent Guidelines and Standards to Boost Quality 165
OTC Drugs Leads the Profit Tables 165
Traditional Chinese Medicine to Prosper 166
Boom Time for Chinese API Suppliers 166
Consolidation to Strengthen the Industry 166
Overview 166
Outlook 166

12b. India 167
Market Overview 167
Too Fragmented Industry 167
Hot Destination for Foreign Players 167
Indian Pharmaceutical Industry to Surge 167
Contract Research to Develop Indian Pharma Industry 167
India Vies for Big Share in Pharmaceutical Outsourcing 167
Noteworthy Foreign Investments in India’s Pharma Market in the
Past 168
Indian Acquisitions of Foreign Operations in the Past 168
Select Indo-US Strategic Partnerships and Alliances 169
Indo-US Synergies in Pharmaceuticals 170
Table 108: Indo-US Macro Market Facts 170
Table 109: Generic Opportunities in the US and Indian
Presence: 2005-2006 171

Table 110: Generic Opportunities in the US and Indian
Presence: 2007 171

Table 111: Generic Opportunities in the US and Indian
Presence: 2008 172

Table 112: Alliances between Select Indo-US Generic Players 172
Contract manufacturing by Indian Companies Expected to Rise
Exponentially - Select Recent Strategic Alliances 172
Indian Pharma - A SWOT Analysis 173
Strengths 173
Weaknesses 173
Opportunities 173
Threats 173
Indian Pharma Sector (pre- and post- patent reform) 173
New Opportunities and Challenges for the US Players 174
Table 113: ANDA Filings by Indian Companies Exponential
Growth & Potential 174
Table 114: India Only Second to the US in DMF Filings:
2003-2004 174
Growing Presence of Indian Players in Europe 175
Promoting Factors 175
Therapeutic Areas 176
Growth Strategies 176
Table 115: Contracted Pharmaceutical and Biotechnology
Clinical Research, Chemical Synthesis, and Analysis Services
Market for India 176
Surfacing Trends - Generic Drugs 176
Table 116: Indian Market for Generic Drugs: Annual Sales
Estimates in US$ Million for bears 2003 through 2008 177
Pharma Outsourcing 177
TRIPS and Pharmaceuticals 177
Leading Pharmaceutical Companies 177
Table 117: Indian Chemical Industry Output for
Pharmaceuticals: Annual Market Estimates for 2003 through
2008 in Billions of US$ 177

Table 118: Pharmaceutical Sales in India: Annual Market
Estimates for 2003 through 2008 in Billions of Indian Rupees 178

Table 119: Largest Indian Companies By Market Capitalization
(As Of October 2005) 178

Table 120: R&D Spend by Major Indian Pharmaceutical Companies-
A Comparison from 2004 through 2008 (In US$ Million) 179

Table 121: Leading Indian Companies - FDA Approved Facilities 179

Table 122: DMF Filings By Leading Indian Companies: 2004 180

12c. Korea 180
Market Overview 180

13. Malaysia 181
Industry Overview 181
Enhancement of Pharmaceuticals 181

14. Latin America 181

14a. Brazil 181
Governing Facts 181
Initiatives 181
Market Scenario 182
Table 123: Pharmaceuticals Value Shipments in Brazil: Annual
Market Estimates for 2003 through 2008 in Billions of US$ 182
Generic Drugs 182
Table 124: Brazilian Market for Generic Drugs: Annual Sales
Estimates in US$ Million for Years 2003 through 2008 182

Table 125: Leading Players in Brazilian Generic Drugs Market
(2004 & 2005): Percentage Breakdown of Volume Sales for
Medley, EMS Sigma Pharma, Biosintetica, Eurofarma, Ranbaxy,
Apotex, Merck, Novartis, and Others 183


GLOBAL DIRECTORY